Rochester, NY 8/8/2009 6:55:38 AM
After Hours - Amgen Inc., AMGN - During the Face 3 Trial Amgen Bone Drug Shows Promising Results
Amgen Inc.
Amgen Inc.'s current test conducted on the company's denosumab drug showed promising results, this is the latest study that the Amgen is running to develop denosumab’s compound's ability to preserve bone integrity in cancer patients.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Amgen has been touting the compound, which could be a blockbuster drug. A month ago, the drug company released results of a similar study that found the bone drug was superior to Novartis AG's Zometa in preventing complications related to the spread of cancer to bones.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
